Hostname: page-component-6898cfcb55-zsp5v Total loading time: 0 Render date: 2026-11-11T06:37:17.463Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Considerations in Selecting and Using Atypical Antipsychotics

Published online by Cambridge University Press:  07 November 2014

John W. Newcomer
Get accessRights & Permissions [Opens in a new window]

Abstract

Patients with schizophrenia have a 20% shorter lifespan than people without the disorder. An increased risk of cardiovascular morbidity and mortality is also associated with schizophrenia. Atypical antipsychotics may contribute to the prevalence of cardiovascular disease by causing weight gain and increased adiposity, risk of insulin resistance, hyperglycemia, diabetes, and hyperlipidemia. Atypical antipsychotics that produce the greatest degree of weight gain also appear to impose the greatest risk of diabetes and hyperlipidemia. Recent evidence suggests that atypical antipsychotics may even affect glucose and lipid metabolism independent of weight gain. Among the currently marketed antipsychotics, clozapine and olanzapine appear to produce the greatest degree of weight gain. Moderate increases in weight are also observed with quetiapine and risperidone. Only ziprasidone and aripiprazole appear to be weight neutral. Atypical antipsychotics that produce the greatest degree of weight gain also appear to carry the greatest risk of diabetes and hyperlipidemia. Because of the potential for atypical antipsychotics to cause weight gain and adversely affect glucose and lipid metabolism, clinical monitoring of these parameters is critical. Dietary modification and exercise may be critical to addressing antipsychotic-induced weight gain and its consequences. In patients with persistent weight gain, evaluation of the risks and benefits of ongoing medications and consideration of switching to an antipsychotic with lower weight-gain liability may improve health outcomes.

Information

Type
Academic Supplement
Information
CNS Spectrums , Volume 10 , Issue S10: Recent Advances in the Clinical Use of Atypical Antipsychotics , August 2005, pp. 12 - 19
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Jibson, MD, Tandon, R. New atypical antipsychotic medications. J Psychiatr Res. 1998;32:215–228.Google Scholar
2.Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.Google Scholar
3.Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–850.Google Scholar
4.Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparen, P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21–28.CrossRefGoogle ScholarPubMed
5.Dmss, BG, Bradford, WD, Rosenheck, RA, Radford, MJ, Krumholz, HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58:565–572.Google Scholar
6.National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Institutes of Health; 1998.Google Scholar
7.Allebeck, P. Schizophrenia: a life-shortening disease. Schizophr Bull. 1989;15:81–89.Google Scholar
8.Allison, DB, Heo, M, Flanders, DW, Faith, MS, Carpenter, KM, Williamson, DESimulation study of the effects of excluding early deaths on risk factor—mortality analyses in the presence of confounding due to occult disease: the example of body mass index. Ann Epidemiol. 1999a;9:132–142.Google Scholar
9.Dixon, L, Postrado, L, Delahanty, J, Fischer, PJ, Lehman, A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J New Mem Dis. 1999;187:496–502.Google Scholar
10.Herran, A, de Santiago, A, Sandoya, M, Fernandez, MJ, Diez-Manrique, JF, Vazquez-Barquero, JLDeterminants of smoking behaviour in outpatients with schizophrenia. Schizophr Res. 2000;41:373–381. N1H publication 98-4083.Google Scholar
11.Davidson, S, Judd, F, Jolley, D, Hocking, B, Thompson, S, Hyland, B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196–202.Google Scholar
12.Wilson, PW, D'Agostino, RB, Levy, D, Belanger, AM, Silbershatz, H, Kannel, WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.Google Scholar
13.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.Google Scholar
14.Kato, MM, Currier, MB, Gomez, CM, Hall, L, Gonzalez-Bianco, M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6:74–77.Google Scholar
15.Ford, ES, Giles, WH, Mokdad, AH. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care. 2004;27:2444–2449.Google Scholar
16.Resnick, HE, Valsania, P, Halter, JB, Lin, X. Differential effects of BM1 on diabetes risk among black and white Americans. Diabetes Care. 1998;21:1828–1835.Google Scholar
17.Banerji, MA, Lebowitz, J, Chaiken, RL, Gordon, D, Krai, JG, Lebovitz, HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997;273:E425–E432.Google Scholar
18.DeFronzo, RA. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM [Lilly Lecture 1987]. Diabetes. 1988;37:667–686.Google Scholar
19.Olefsky, JM, Farquhar, JW, Reaven, GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551–560.Google Scholar
20.Nasrallah, HA, Mulvihill, T. Iatrogenic disorders associated with conventional vs. atypical antipsychotics. Ann Clin Psychiatry. 2001;13:215–227.Google Scholar
21.Rosack, J. FDA to require diabetes warning on antipsychotics. Psychiatric News. 2O03;38:1–5. Available at: http://pn.psychiatryonline.org/cgi/content/full/38/20/la. Accessed October 31, 2004.Google Scholar
22.Allison, DB, Mentore, JL, Heo, M, et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999b; 156:1686–1696.Google Scholar
23.Ayd, F Jr. Highlights of New Schizophrenia Research, III. Available at: http://www.mhsource.com/schizophrenia/highlights3.html. Accessed November 5, 2004.Google Scholar
24.Kane, JM, Carson, WH, Saha, AR, et al.Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763–771.Google Scholar
25.Nemeroff, CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997;58(suppl 10):45–49.Google Scholar
26.Kinon, BJ. The routine use of atypical antipsychotic agents: maintenance treatment. J Ciin Psychiatry. 1998;59(suppl 19):18–22.Google Scholar
27. Data on file, Janssen Pharmaceutica.Google Scholar
28. Data on file, Pfizer Inc.Google Scholar
29. Data on file, Bristol-Myers Squibb and Company.Google Scholar
30.Koller, E, Schneider, B, Bennett, K, Dubitsky, G. Clozapine-associated diabetes. Am J Med. 2001;111:716–723.Google Scholar
31.Koller, EA, Doraiswamy, PM. Olanzapine-associated diabetes mellitus. Pharmocotherapy. 2002;22:841–852.Google Scholar
32.Koller, EA, Cross, JT, Doraiswamy, PM, Schneider, BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735–744.Google Scholar
33.Koller, EA, Weber, J, Doraiswamy, PM, Schneider, BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65:857–863.Google Scholar
34.Yang, SH, McNeely, MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry. 2002;159:1435.Google Scholar
35.Wirshing, DA, Boyd, JA, Meng, LR, Ballon, JS, Marder, SR, Wirshing, WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856–865.Google Scholar
36.Gianfrancesco, F, Durkin, MB, Mahmoud, R, Wang, RH. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics. 2002;20:413–427.Google Scholar
37.Koro, CE, Fedder, DO, L'ltalien, GJ, et al.Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J. 2002a;325:243.Google Scholar
38.Caro, JJ, Ward, A, Levinton, C, Robinson, K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135–1139.Google Scholar
39.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.Google Scholar
40.Pigott, TA, Carson, WH, Saha, AR, et al.Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048–1056.Google Scholar
41.Newcomer, JW, Haupt, DW, Fucetola, R, et al.Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337–345.Google Scholar
42.Henderson, DC, Cagliero, E, Gray, C, et al.Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–981.Google Scholar
43.Meyer, JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369–374.Google Scholar
44.Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 20O2;63:425–433.Google Scholar
45.Koro, CE, Fedder, DO, L'Italien, GJ, et al.An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002b;59:1021–1026.Google Scholar
46. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (Ziprasidone HCl). July 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgtd/3619bla.pdf. Accessed March 2005.Google Scholar
47.McQuade, RD, Jody, D, Kujawa, MJ, et al. Long-term weight effects of aripiprazole versus olanzapine. Poster presented at: 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.Google Scholar
48.L'Italien, GJ. Pharmacoeconomic impact of antipsychotic-induced metabolic events. Prev Med Managed Care. 2003;3(suppl 2):S38–S42.Google Scholar
49.Henderson, DC, Daley, TB, Kunkel, L, Rodrigues-Scott, M, Koul, P, Hayde, D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry. 2004;65:686–689.Google Scholar
50.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.CrossRefGoogle Scholar
51.Aquila, R, Emanuel, M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry. 2000;2:2O–23.Google Scholar
52.Menza, M, Vreeland, B, Minsky, S, Gara, M, Radler, DR, Sakowitz, M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004;65:471–477.Google Scholar
53.Weiden, PJ, Daniel, DG, Simpson, G, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595–600.Google Scholar
54.Weiden, PJ, Daniel, DG, Leobel, AD, Warrington, L, Dunn, J, Murray, SR. Course of weight and metabolic benefits one year after switching to ziprasidone. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
55.Casey, DE, Carson, WH, Saha, AR, et al.Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391–399.CrossRefGoogle ScholarPubMed
56.Ried, LD, Renner, BT, Bengtson, MA, Wilcox, BM, Acholonu, WW Jr.Weight change after an atypical antipsychotic switch. Ann Phormacother. 2003;37:1381–1386.Google Scholar
57.Berry, S, Mahmoud, R. Improvement of insulin indices after switch from olanzapine to risperidone. Eur Neuropsychopharmocol. 2002;12(suppl 3):S316.Google Scholar